FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136113077> ?p ?o ?g. }

• W3136113077 endingPage "1573" @default.
• W3136113077 startingPage "1561" @default.
• W3136113077 abstract "Abstract STUDY QUESTION Which chemotherapeutic agents and body site-specific radiation fields are dose-dependently associated with an increased risk of fertility impairment in long-term female childhood, adolescent and young adulthood (CAYA) cancer survivors? SUMMARY ANSWER Busulfan, lower abdominal radiotherapy (RT) and total body irradiation (TBI) seem to be associated with fertility impairment at any dose, whereas gonadotoxicity of melphalan and procarbazine is suggested at medium/high (&gt;140 mg/m2) or high dose (&gt;5600 mg/m2) therapy, respectively. WHAT IS KNOWN ALREADY Several treatment-related fertility deficits, as assessed by both self-reported outcomes and hormonal markers are known to occur following treatment of CAYA cancer. However, knowledge regarding precise dose-related estimates of these treatment-related risks are scarce. STUDY DESIGN, SIZE, DURATION The current case–control study was nested within the PanCareLIFE cohort study. In total, 1332 CAYA survivors from 8 countries, 9 institutions and 11 cohorts, participated in and contributed data to the study. PARTICIPANTS/MATERIALS, SETTING, METHODS All participants were female 5-year CAYA cancer survivors. In total, 450 cases (fertility impaired survivors) and 882 matched controls (not fertility impaired survivors) were included. Fertility impairment was defined using both questionnaire data (primary or secondary amenorrhea; use of artificial reproductive techniques; unfulfilled wish to conceive) and hormonal data (FSH and anti-Müllerian hormone (AMH)). Multivariable logistic regression models were used to investigate the effect of (i) alkylating agent exposure, and (ii) dose categories for individual chemotherapeutic agents and for RT-exposed body sites. MAIN RESULTS AND THE ROLE OF CHANCE A positive dose–effect relationship between cyclophosphamide equivalent dose (CED) score and fertility impairment was found, with survivors with a CED score &gt; 7121 mg/m2 being at a significantly increased risk of fertility impairment (odds ratio (95% CI) = 2.6 (1.9–3.6) P &lt; 0.001). Moreover, cumulative dose variables of the following treatments were significantly associated with fertility impairment: busulfan, carmustine, cyclophosphamide, melphalan, procarbazine, lower abdominal RT and TBI. Busulfan, lower abdominal RT and TBI seem to be associated with fertility impairment at any dose, whereas gonadotoxicity of melphalan and procarbazine is suggested at medium/high (&gt;140 mg/m2) or high dose (&gt;5600 mg/m2) therapy, respectively. LIMITATIONS, REASONS FOR CAUTION Our study may have been subject to selection bias since data from about half of the original base cohorts were available for the current study. This could impact the generalizability of our study results. WIDER IMPLICATIONS OF THE FINDINGS We identified survivors at high risk for fertility impairment and, consequently, for a reduced or even absent reproductive life span. Both girls and young women who are about to start anti-cancer treatment, as well as adult female survivors, should be counselled about future parenthood and referred to a reproductive specialist for fertility preservation, if desired. STUDY FUNDING/COMPETING INTEREST(S) This study has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 602030. There are no competing interests. TRIAL REGISTRATION NUMBER n/a" @default.
• W3136113077 created "2021-03-29" @default.
• W3136113077 creator A5000426144 @default.
• W3136113077 creator A5000788245 @default.
• W3136113077 creator A5002736598 @default.
• W3136113077 creator A5006456420 @default.
• W3136113077 creator A5010670707 @default.
• W3136113077 creator A5016039667 @default.
• W3136113077 creator A5023622959 @default.
• W3136113077 creator A5026572030 @default.
• W3136113077 creator A5030601121 @default.
• W3136113077 creator A5035945818 @default.
• W3136113077 creator A5037623587 @default.
• W3136113077 creator A5041274617 @default.
• W3136113077 creator A5045183692 @default.
• W3136113077 creator A5050108182 @default.
• W3136113077 creator A5051526423 @default.
• W3136113077 creator A5058576621 @default.
• W3136113077 creator A5058752491 @default.
• W3136113077 creator A5059586220 @default.
• W3136113077 creator A5060546126 @default.
• W3136113077 creator A5062805582 @default.
• W3136113077 creator A5064488280 @default.
• W3136113077 creator A5065228177 @default.
• W3136113077 creator A5083545252 @default.
• W3136113077 creator A5086523576 @default.
• W3136113077 creator A5088388014 @default.
• W3136113077 date "2021-03-21" @default.
• W3136113077 modified "2023-10-17" @default.
• W3136113077 title "Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE)" @default.
• W3136113077 cites W1497439354 @default.
• W3136113077 cites W1839076539 @default.
• W3136113077 cites W1976281058 @default.
• W3136113077 cites W1982201870 @default.
• W3136113077 cites W1986432750 @default.
• W3136113077 cites W1996989587 @default.
• W3136113077 cites W2005056331 @default.
• W3136113077 cites W2015885334 @default.
• W3136113077 cites W2035437353 @default.
• W3136113077 cites W2052334717 @default.
• W3136113077 cites W2054868293 @default.
• W3136113077 cites W2056279505 @default.
• W3136113077 cites W2060608747 @default.
• W3136113077 cites W2067799640 @default.
• W3136113077 cites W2085797732 @default.
• W3136113077 cites W2086535934 @default.
• W3136113077 cites W2100827666 @default.
• W3136113077 cites W2107910796 @default.
• W3136113077 cites W2112309180 @default.
• W3136113077 cites W2137895742 @default.
• W3136113077 cites W2143608188 @default.
• W3136113077 cites W2144504411 @default.
• W3136113077 cites W2155695527 @default.
• W3136113077 cites W2171010262 @default.
• W3136113077 cites W2194520815 @default.
• W3136113077 cites W2303955852 @default.
• W3136113077 cites W2363867823 @default.
• W3136113077 cites W2482801690 @default.
• W3136113077 cites W2552990673 @default.
• W3136113077 cites W2602089190 @default.
• W3136113077 cites W2618696300 @default.
• W3136113077 cites W2782758263 @default.
• W3136113077 cites W2794761832 @default.
• W3136113077 cites W2805820896 @default.
• W3136113077 cites W2805957413 @default.
• W3136113077 cites W2816555100 @default.
• W3136113077 cites W2892423829 @default.
• W3136113077 cites W2894667403 @default.
• W3136113077 cites W2910767932 @default.
• W3136113077 cites W2912644484 @default.
• W3136113077 cites W2917244549 @default.
• W3136113077 cites W2936177944 @default.
• W3136113077 cites W4248331815 @default.
• W3136113077 doi "https://doi.org/10.1093/humrep/deab035" @default.
• W3136113077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33744927" @default.
• W3136113077 hasPublicationYear "2021" @default.
• W3136113077 type Work @default.
• W3136113077 sameAs 3136113077 @default.
• W3136113077 citedByCount "18" @default.
• W3136113077 countsByYear W31361130772021 @default.
• W3136113077 countsByYear W31361130772022 @default.
• W3136113077 countsByYear W31361130772023 @default.
• W3136113077 crossrefType "journal-article" @default.
• W3136113077 hasAuthorship W3136113077A5000426144 @default.
• W3136113077 hasAuthorship W3136113077A5000788245 @default.
• W3136113077 hasAuthorship W3136113077A5002736598 @default.
• W3136113077 hasAuthorship W3136113077A5006456420 @default.
• W3136113077 hasAuthorship W3136113077A5010670707 @default.
• W3136113077 hasAuthorship W3136113077A5016039667 @default.
• W3136113077 hasAuthorship W3136113077A5023622959 @default.
• W3136113077 hasAuthorship W3136113077A5026572030 @default.
• W3136113077 hasAuthorship W3136113077A5030601121 @default.
• W3136113077 hasAuthorship W3136113077A5035945818 @default.
• W3136113077 hasAuthorship W3136113077A5037623587 @default.
• W3136113077 hasAuthorship W3136113077A5041274617 @default.
• W3136113077 hasAuthorship W3136113077A5045183692 @default.
• W3136113077 hasAuthorship W3136113077A5050108182 @default.
• W3136113077 hasAuthorship W3136113077A5051526423 @default.

• next